Fusion AntibodiesLSE:FAB +4.55%32 Days Payable is 160.42 as of Sep. 2025, which is 114% above its 10-year median of 74.79. GuruFocus rates LSE:FAB with a GF Score™ of 32/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 703 Biotechnology companies, Fusion Antibodies ranks better than 55.62% on this metric.
The historical rank and industry rank for Fusion Antibodies's Days Payable or its related term are showing as below:
LSE:FAB'
s Days Payable Range Over the Past 10 Years
Min: 63.36 Med: 74.79 Max: 142.4
Current: 142.4
During the past 11 years, Fusion Antibodies's highest Days Payable was 142.40. The lowest was 63.36. And the median was 74.79.
LSE:FAB's Days Payable is ranked better than 55.62% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs LSE:FAB: 142.40
Fusion Antibodies's Days Payable
increased
from Sep. 2024 (72.42) to Sep. 2025 (160.42).
It may suggest that Fusion Antibodiesdelayed paying its suppliers.
Fusion Antibodies Days Payable Related Terms
Fusion Antibodies Days Payable Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Fusion Antibodies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Days Payable distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fusion Antibodies's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Days Payable of 160.42 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fusion Antibodies and its competitors. This is 114% above median its historical median of 74.79. Over the past decade, Fusion Antibodies' Days Payable has ranged from 63.36 to 142.40. According to the industry distribution chart, Fusion Antibodies ranks #312 out of 703 companies in the Biotechnology industry, placing it in the top 44.4%.
Is Fusion Antibodies' Days Payable too high?
Fusion Antibodies' current Days Payable of 160.42 is 114% above median its 10-year median of 74.79. Over the past 10 years, this metric has ranged from a low of 63.36 to a high of 142.40. The Biotechnology industry median Days Payable is 113.76. Fusion Antibodies' value of 160.42 is 41% above this industry median. Based on the distribution chart, Fusion Antibodies ranks #312 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #312 out of 703 companies for Days Payable. This puts Fusion Antibodies in the upper half of its industry. The industry median Days Payable is 113.76. Fusion Antibodies' value of 160.42 is 41% above this benchmark. Historically, Fusion Antibodies' own Days Payable has ranged from 63.36 to 142.40 over the past decade. While the company's 10-year median is 74.79 vs. the industry median of 113.76, Fusion Antibodies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current Days Payable of 160.42 is 41% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Days Payable is 160.42, which is 114% above median its own 10-year median of 74.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 187.5% above its estimated fair value. The current Days Payable is 160.42, which is 114% above median its 10-year median of 74.79 and 41% above the Biotechnology industry median of 113.76. Fusion Antibodies' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Days Payable is 160.42 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.12 is trading 187.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Days Payable: 160.42 (114% above median its 10-year median of 74.79)
GF Value™: £0.04 vs. price of £0.12 (187.5% above fair value)
Industry Position: 41% above the Biotechnology median (#312 of 703)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
32GF Score
Get the complete analysis for LSE:FAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
